Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sanqi Huoluo Plaster
- Development stage
- Phase 2
- Lead developer
- Guangzhou University of Chinese Medicine
- Administration
- Topical
01
Overview
Sanqi Huoluo Plaster is a Traditional Chinese Medicine (TCM) topical formulation developed by Guangzhou University of Chinese Medicine. It is primarily indicated for the treatment of acute closed soft tissue injuries characterized by the TCM pattern of qi stagnation and blood stasis. The formulation likely contains *Panax notoginseng* (Sanqi) as a key active ingredient, which is traditionally used to resolve blood stasis, reduce swelling, and alleviate pain. It is administered as a topical plaster to the affected area to promote functional recovery and provide pain relief. The drug has been evaluated in randomized, double-blind, placebo-controlled Phase II clinical trials in China.
- Other names
- Sanqi Huoluo Tie
Beyond the preview
Go deeper on Sanqi Huoluo Plaster.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sanqi Huoluo Plaster.